Ethics of GLP-1s and medicalizing wellbeing

Raiany weighs safety, efficacy, and fairness concerns for GLP-1s and argues ethics hinge on risk and accessibility.

Play episode from 34:19

chevron_right

Transcript

chevron_right

Transcript

Episode notes

On this months edition of The WHOOP Podcast, WHOOP SVP of Research, Algorithms, and Data Emily Capodilupo sits down with longevity researcher, bioethicist, Scholar in Residence at the American Federation for Aging Research, Dr. Raiany Romanni-Klein to explore how society should be handling aging.

Dr. Romanni-Klein breaks down why aging may be the most underfunded and misunderstood driver of suffering in modern society, and why treating it as a solvable biological problem could transform our economy, healthcare system, and future. From the ethics of longevity to the policy failures slowing innovation, Dr. Rommani-Klein explains that extending healthspan is all about reducing disease, caregiver burden, and economic strain.

The conversation dives into the science and economics of aging, including why brain health may offer the highest return on investment, the opportunities of the pharmaceutical industry in creating longevity drugs, and why exercise and diet remain the most powerful longevity tools we have today. Emily and Dr. Rommani-Klein the regulatory and incentive barriers preventing large-scale aging trials and what would need to change for society to treat aging as a disease.

(00:33) Introduction to Dr. Raiany Romanni-Klein

(01:17) Where Is The Intersection of Ethics and Longevity Science?

(02:05) The Aging Population and Reduced Birth Rates

(04:31) WHOOP Podcast Rapid Fire Q’s

(07:42) Ethics Around Technological Evolution: What Is Best For Longevity & Society

(11:41) Changing Perspectives on Longevity

(17:42) What Biomarkers Are Important For Longevity

(22:09) Incentives For Pharmaceutical Companies to Invest In Longevity Science

(24:51) Do People Have The Agency To Extend Healthspan?

(27:16) Policy Issues Affecting Longevity

(34:18) The Influence of Longevity Drugs Like GLP-1s

(42:10) Is There A Better System The US Should Be Following?